Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,440.00
Bid: 1,431.00
Ask: 1,433.00
Change: 12.00 (0.84%)
Spread: 2.00 (0.14%)
Open: 1,439.00
High: 1,448.00
Low: 1,417.00
Prev. Close: 1,428.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior Names Promotes Finance Head Crossley To CEO, Thaxter Departs

Mon, 29th Jun 2020 10:29

(Alliance News) - Indivior PLC on Monday said Chief Financial & Operations Officer Mark Crossley will replace Shaun Thaxter as chief executive with immediate effect.

Thaxter, in mutual agreement with the board, is stepping down as chief executive and executive director, the company added.

Indivior shares were trading 0.5% lower at 78.40 pence each on Monday morning in London.

Crossley has been chief financial and operations officer of the drug manufacturer since February 2017. He was chief strategy officer from 2014 to 2017 and also served as finance director where he led the demerger of Indivior from Reckitt Benckiser Group PLC.

Indivior said Ryan Preblick has been appointed interim chief financial officer, adding that it will commence a search for a permanent finance chief and assess whether to hire a separate operations officer. Preblick is currently senior vice president Global Financial Planning & Analysis Commercial Operations, a role he stepped into in January. He joined Indivior in 2012 as regional finance controller for North America, later becoming vice president US Finance.

"Indivior's vision is to ensure patients all around the world have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Mark is a proven leader with a broad strategic and financial skill-set and a deep understanding of the company's guiding principles. The board has full confidence in his ability to drive Indivior forwards and to pursue its vision for the benefit of all stakeholders," said Interim Chair Daniel Tasse.

By Ife Taiwo; ifetaiwo@alliancenews.com.

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
16 Feb 2023 16:55

LONDON MARKET CLOSE: Records for FTSE and CAC but US PPI hits New York

(Alliance News) - Blue-chip benchmarks in London and Paris hit record highs on Thursday, with the FTSE 100 managing to cling to its daily gain, despite some weakness following US producer price data.

Read more
16 Feb 2023 12:19

CORRECT: LONDON MARKET MIDDAY: FTSE 100 stays above 8,000

(Correcting the GBPUSD quote).

Read more
16 Feb 2023 12:07

LONDON MARKET MIDDAY: FTSE 100 stays above 8,000 as Centrica jumps

(Alliance News) - Stock prices in London were higher at midday on Thursday, with London's flagship index still trading above the 8,000 mark on the back of strong performances from Centrica and Relx.

Read more
16 Feb 2023 10:10

CORRECT: Indivior shares down on swing to annual loss

(Correcting litigation provision is against 2022 results.)

Read more
16 Feb 2023 10:09

TOP NEWS: Indivior shares down on swing to annual loss

(Alliance News) - Indivior PLC on Thursday reported a swing to a full-year loss due to a provision for litigation, despite net revenue jumping by 14% due to growth in its Sublocade injection.

Read more
16 Feb 2023 08:49

LONDON MARKET OPEN: FTSE 100 tops 8,000; Centrica is star performer

(Alliance News) - Stock prices in London opened higher on Thursday, with London's blue-chip index pushing past the 8,000 mark once again, a day after it first broke the barrier.

Read more
16 Feb 2023 07:55

LONDON BRIEFING: Centrica, Indivior swing to loss; StanChart bullish

(Alliance News) - Stocks in London were set to open higher on Thursday, with the FTSE 100 called to push past the 8,000 mark again at the open.

Read more
16 Feb 2023 07:54

Indivior shares tumble as group sets aside $290m for US litigation

(Sharecast News) - Shares in pharmaceuticals business Indivior tumbled early on Thursday after the group revealed it had put aside $290.0m for ongoing litigation in the States.

Read more
9 Feb 2023 15:47

UK earnings, trading statements calendar - next 7 days

Friday 10 February 
Ince Group PLCFull Year Results (TBC)
Lancashire Holdings LtdFull Year Results
S&U PLCTrading Statement
Victrex PLCTrading Statement
Monday 13 February 
no events scheduled 
Tuesday 14 February 
Carr's Group PLCFull Year Results
Coca-Cola HBC AGFull Year Results
Plus500 LtdFull Year Results
Tui AGQ1 Results
UP Global Sourcing Holdings PLCTrading Statement
Wednesday 15 February 
Barclays PLCFull Year Results
Brunner Investment Trust PLCFull Year Results
Dunelm Group PLCHalf Year Results
Equipmake Holdings PLCHalf Year Results
Glencore PLCFull Year Results
Hargreaves Lansdown PLCHalf Year Results
Pan African Resources PLCHalf Year Results
Thursday 16 February 
Centrica PLCFull Year Results
Coca-Cola Europacific Partners PLCFull Year Results
Indivior PLCFull Year Results
MJ Gleeson PLCHalf Year Results
Moneysupermarket.com Group PLCFull Year Results
Relx PLCFull Year Results
Riverstone Credit Opportunities Income PLCFull Year Results
South32 LtdHalf Year Results
Standard Chartered PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
6 Feb 2023 16:32

Indivior announces expiry of waiting period for Opiant purchase

(Alliance News) - Indivior PLC has announced on Monday the expiration of the waiting period relating to its USD145 million purchase of Opiant Pharmaceuticals Inc.

Read more
7 Dec 2022 17:25

LONDON MARKET CLOSE: Pharma stocks fail to lift FTSE 100 in the green

(Alliance News) - Stocks in London closed in the red on Wednesday, despite a strong performance from pharmaceutical stocks, as investors digested a raft of economic data from both China and Europe.

Read more
7 Dec 2022 11:44

Indivior targets Nasdaq listing for spring 2023 as hails Sublocade

(Alliance News) - Indivior PLC on Wednesday said it aims to list on the Nasdaq in spring 2023 as it expects its injection Sublocade to reach peak annual net revenue of over USD1.5 billion.

Read more
7 Dec 2022 08:59

Indivior raises guidance for peak net revenue potential of Sublocade asset

(Sharecast News) - Pharmaceuticals business Indivior upgraded guidance for the peak annual net revenue potential of its Sublocade asset on Wednesday ahead of its Capital Markets Day event in New York City.

Read more
14 Nov 2022 11:16

Indivior buys Opiant creating "comprehensive" treatment platform

(Alliance News) - Indivior PLC on Monday announced the acquisition of Opiant Pharmaceuticals Inc for around USD145 million.

Read more
14 Nov 2022 07:05

Indivior to buy US overdose treatment firm Opiant for $145m

(Sharecast News) - UK-based drug company Indivior said it would pay $145m for Opiant Pharmaceuticals which produces treatments to overcome opioid addiction.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.